Humana Inc.
NYSE:HUMMedical - Healthcare Plans
+$0.70 today
- Market cap
- $46.32B
- Beta
- 0.77
- P/E (TTM)
- 38.6
- EPS (TTM)
- $9.39
- Dividend yield
- 0.98%
Volume 4.06M
Average 1.72M
HUM Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Humana Inc.NYSE: HUM
Cost of Revenue · Q3 FY2026 · quarter ended Sep 2026
Cost of revenue growth accelerates
Q3 FY2026 cost of revenue of $36.32B rose 29.8% year over year, ahead of the +24.8% change in trailing-twelve-month cost of revenue. Sequentially, it rose 2.7% from the prior quarter. Over 3 fiscal years it compounded at +13.5% a year.
Context
- Cost of revenue amounted to 85.5% of revenue in FY2025, unchanged from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +29.8% holds above the trailing-twelve-month pace of +24.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 110.81B USD
- Year-over-year change
- +10.1%
- 4-year CAGR
- +12.5%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 110.81B | +10.1% |
| FY2024 | 2024-12-31 | 100.66B | +13.9% |
| FY2023 | 2023-12-31 | 88.39B | +16.8% |
| FY2022 | 2022-12-31 | 75.69B | +9.4% |
| FY2021 | 2021-12-31 | 69.2B | — |
Cost of Revenue vs competitors
How HUM compares with its peers on the latest reported figures
- HUM's LTM Sep 2026 cost of revenue of $134.12B is the 5th highest of the 9 companies compared; the peer median is $145.27B.
- Its year-over-year change of +24.8% is the 2nd highest of 9, against a peer median of +3.3%.
- Cost of revenue amounts to 87.0% of revenue for HUM, versus a peer median of 84.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $356.34B | +6.9% | +9.0% | 85.8% | |
| LTM Sep 2026 | $347.08B | -0.7% | +14.2% | 77.2% | |
| LTM Sep 2026 | $256.93B | +6.5% | +16.6% | 89.7% | |
| LTM Jun 2026 | $162.49B | +0.1% | +10.2% | 83.9% | |
| LTM Sep 2026 | $134.12B | +24.8% | +13.5% | 87.0% | |
| LTM Sep 2026 | $128.05B | -10.9% | +8.3% | 63.4% | |
| LTM Sep 2026 | $40.11B | +0.1% | +13.8% | 91.9% | |
| LTM Jun 2026 | $8.44B | +22.7% | — | 55.1% | |
| LTM Mar 2026 | $3.73B | +40.5% | +40.4% | 87.6% | |
| Peer median (excluding HUM) | $145.27B | +3.3% | +13.8% | 84.9% | |
Competitors are the stored peer set for HUM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 83.65B | 92.92B | 106.44B | 117.81B | 129.66B |
| Cost of Revenue | 69.2B | 75.69B | 88.39B | 100.66B | 110.81B |
| Gross Profit | 14.45B | 17.23B | 18.05B | 17.15B | 18.85B |
| Gross Margin | 17.3% | 18.5% | 17.0% | 14.6% | 14.5% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses | 11.03B | 13.67B | 14.73B | 15.52B | 17.4B |
| Depreciation & Amortization | 713M | 845M | 917M | 968M | 824M |
| EBITDA | 4.46B | 4.81B | 4.73B | 3.26B | 2.91B |
| EBITDA Margin | 5.3% | 5.2% | 4.4% | 2.8% | 2.2% |
| Operating Income | 3.42B | 3.56B | 3.32B | 1.63B | 1.45B |
| Operating Margin | 4.1% | 3.8% | 3.1% | 1.4% | 1.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 326M | 401M | 493M | 660M | 631M |
| Other Income / Expenses | 0 | 0 | 0 | 0 | 0 |
| Income Before Tax | 3.42B | 3.56B | 3.32B | 1.63B | 1.45B |
| Pre-Tax Margin | 4.1% | 3.8% | 3.1% | 1.4% | 1.1% |
| Income Tax Expense | 485M | 762M | 836M | 413M | 250M |
| Net Income | 2.93B | 2.81B | 2.49B | 1.21B | 1.19B |
| Net Margin | 3.5% | 3.0% | 2.3% | 1.0% | 0.9% |
| EPS (Basic) | 22.79 | 22.20 | 20.09 | 10.01 | 9.87 |
| EPS (Diluted) | 22.67 | 22.08 | 20.00 | 9.98 | 9.84 |
| Weighted Avg Shares | 128.69M | 126.42M | 123.87M | 120.57M | 120.45M |
| Weighted Avg Shares (Diluted) | 129.4M | 127.09M | 124.44M | 120.87M | 120.83M |
Humana Inc.
NYSE:HUM
Intrinsic Alpha fair value
Locked
Current Price
$385.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.